{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-252180","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2022-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.532572+00:00","generated_at":"2026-06-23T07:15:19.647722+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"4D Molecular Therapeutics appoints Noriyuki Kasahara to Board, promotes Fred Kamal to President and COO","bullets":["Appointed Noriyuki Kasahara, M.D., Ph.D., to Board as Class I director and Chair of Science and Technology Committee.","Promoted Fred Kamal, Ph.D., to President and COO; base salary increased to $475,000, annual target bonus 45%.","Granted Kasahara option for 45,000 shares at $8.06; Kamal granted option for 15,000 shares at $8.06.","Kasahara is Professor at UCSF with 30+ years in gene therapy, author of 150+ articles, inventor on 18 patents."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-252180","json":"https://secwatch.observer/filing/0001193125-22-252180.json","markdown":"https://secwatch.observer/filing/0001193125-22-252180.md","text":"https://secwatch.observer/filing/0001193125-22-252180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/0001193125-22-252180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/d404270d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:15:19.647722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"799e3999ad","claim":"Fred Kamal changed role as President and Chief Operating Officer at 4D Molecular Therapeutics, Inc..","evidence_excerpt":"appointed Fred Kamal, Ph.D., the Company’s current Chief Operating Officer and Chief Technical Officer, as President and Chief Operating Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/0001193125-22-252180-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"912b16d010","claim":"Noriyuki Kasahara was appointed as Class I director at 4D Molecular Therapeutics, Inc..","evidence_excerpt":"appointed Noriyuki Kasahara, M.D., Ph.D., to the Board as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/0001193125-22-252180-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}